Effect of aspirin on endogenous fibrinolysis in patients with CAD
Research type
Research Study
Full title
ASSESSING THE EFFECT OF ASPIRIN ON ENDOGENOUS FIBRINOLYSIS IN PATIENTS WITH CORONARY ARTERY DISEASE
IRAS ID
235261
Contact name
Diana Gorog
Contact email
Sponsor organisation
East and North Hertfordshire NHS Trust
Duration of Study in the UK
1 years, 6 months, 0 days
Research summary
Coronary artery disease (CAD) is a condition that causes narrowing to the vessels supplying the heart known as the coronary arteries. As a result of this may lead to a reduced blood flow to the heart muscle causing chest pain (angina). This may also lead to an increased risk of forming blood cells becoming “sticky” and clumping together to make a clot inside the arteries, which can block the flow completely, causing a heart attack.
To prevent the blood cells becoming “sticky”, doctors prescribe blood-thinning tablets in an attempt to prevent the formation of blood clots inside the arteries. The best available treatment to date is aspirin, being prescribed at a daily dose of 75mg. However, some people still have a heart attack despite taking aspirin. Several studies have identified a natural protective mechanism our body has, to efficiently break down a blood clot once formed, such that even if a clot is formed, it is rapidly dissolved and no lasting damage is sustained. We would like to assess how aspirin affects this natural protective mechanism. We propose testing blood from patients who are due to be started on aspirin (for clinical indications, prescribed by their doctor) before start of aspirin treatment and again after being established on regular aspirin, to assess whether aspirin treatment has any effect on the natural defense system in the blood to prevent clots.REC name
London - Camden & Kings Cross Research Ethics Committee
REC reference
17/LO/1927
Date of REC Opinion
2 Jan 2018
REC opinion
Further Information Favourable Opinion